Orlistat and Mounjaro: What's the Difference and Does It Matter?

You've been taking orlistat for months and you're wondering if there's something more effective

That's a scenario our prescribers hear regularly. Orlistat has been around for decades, it's familiar, and at 120mg it's available on prescription from a GP or private pharmacy. It does what it says: it blocks the enzyme lipase in your gut so that roughly a third of the fat you eat passes through rather than being absorbed. The catch is that effectiveness depends heavily on sticking to a genuinely low-fat diet. Eat too much fat and your body makes the side effects very clear, very quickly — loose stools, urgency, oily discharge. That's not a manufacturing flaw; it's the mechanism working as intended.

Mounjaro takes a different route entirely. Rather than interfering with fat digestion, tirzepatide acts on two receptors (GIP and GLP-1) that regulate appetite and blood sugar. Your brain receives stronger satiety signals, your stomach empties more slowly, and over time many people find they simply want less food. It doesn't punish dietary fat in the same way; the side-effect profile is gastrointestinal too, but nausea and fullness rather than the urgency that orlistat is associated with. Whether orlistat with Mounjaro could theoretically be combined is a question worth reading about carefully, this page looks at the clinical considerations around taking them together.

The trial results differ substantially. In SURMOUNT-1, tirzepatide produced an average weight reduction of around 20–21% at its highest dose over 72 weeks, in adults with obesity and no diabetes. Orlistat's evidence base puts average additional loss at roughly 3–5% over placebo in most trials, meaning a total loss of around 5–10% when diet is followed properly. That gap is significant. The NHS orlistat page summarises both the benefits and the dietary requirements honestly.

How the licensing and eligibility conditions compare for each medicine

Orlistat at 60mg (Alli) can be sold in a pharmacy without a prescription to adults with a BMI of 28 or above. At 120mg (Xenical), it becomes prescription-only, typically recommended for adults with a BMI of 30 or above, or 28 or above with weight-related conditions. The prescriber checks your starting BMI, cholesterol levels, and whether you're eating the right kind of diet to make orlistat workable.

Mounjaro's licence covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, things like high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The prescriber also checks for conditions that would make tirzepatide unsuitable: a personal or family history of medullary thyroid carcinoma, pancreatitis, or certain gastrointestinal conditions, for instance. BMI alone doesn't settle the matter either way.

Mounjaro is a Black Triangle medicine, meaning it carries additional MHRA monitoring while longer-term data continues to be collected. That's standard for newer medicines and doesn't indicate that it's less safe, it means regulators want robust post-authorisation reporting. Pregnancy, breastfeeding, and trying to conceive are exclusions for both medicines; under-18s are not licensed for Mounjaro. Orlistat and Mounjaro are not the same medicine by mechanism, structure, or approval history, which matters when people ask whether switching is straightforward.

Mounjaro or orlistat: the cost context and what a private prescription actually involves

Orlistat at prescription strength costs relatively little, on the NHS it's dispensed with a standard prescription charge; privately it's inexpensive. Mounjaro is considerably more expensive as a private treatment. Following Eli Lilly's list-price revision in September 2025, typical private prices for tirzepatide range roughly £149–£375 per month depending on dose and provider, as widely reported at the time. That's a meaningful difference from orlistat, and it's worth acknowledging plainly.

If you're weighing up the costs, this page on Mounjaro pricing in the UK sets out what drives the variation and what a private prescription legitimately includes. The short version: a legitimate price covers clinical assessment, the prescription itself, and dispensing, not just the pen. A quote that strips those elements out to look competitive is worth scrutinising.

People sometimes ask whether they can get Mounjaro on the NHS instead, which would change the cost equation entirely. The NHS rollout is phased and currently prioritises patients with a BMI of 40 or above and four or more qualifying conditions. That threshold will drop over time, but waiting lists through specialist services can be long. Private treatment through a regulated pharmacy is the alternative for people who don't yet qualify or prefer not to wait. Mounjaro is dispensed only on a valid UK prescription from a qualified prescriber, not from unverified sellers online. The MHRA has warned repeatedly about counterfeit weight-loss pens circulating through social media channels, some of which have caused serious harm.

What the prescriber actually looks at when you move from orlistat to Mounjaro

If you've been on orlistat and you want to explore tirzepatide, the prescriber's job is to check whether Mounjaro is clinically appropriate for you specifically. They'll ask about your current BMI, your weight-related conditions, any medicines you're already taking (including statins and contraceptives, which can interact differently with tirzepatide), and your history with orlistat, how long you've been taking it, how it's worked, why you're considering switching.

There's no rule preventing someone who has used orlistat from starting Mounjaro, but the prescriber needs the full picture. Interactions with other medicines like statins are one area worth raising at that consultation. Separately, the side-effect profile of tirzepatide is worth understanding before you start, nausea is common in the early weeks after a dose increase, and knowing that in advance helps people manage it rather than stopping unnecessarily.

At nume (sorry, at the practice) a real prescriber reads your consultation the same day. If you order on a Tuesday afternoon in the run-up to a bank holiday, the clinical review still happens that day if you submit before noon; dispatch follows once approval is confirmed. That timing detail matters to people who've planned around a quiet week to start something new. Check your eligibility and start a free consultation if you'd like a prescriber to look at your situation properly.